Antibiotics
Tigecycline
- Brand logo & Packshot - Tigicon™ 50.
- Composition - Each vial contains Tigecycline USP 50 mg.
- Description - Tigecycline is a tetracycline derivative (a glycylcycline) for intravenous infusion. It inhibits protein translation in bacteria by binding to the 50S ribosomal subunit and blocking entry of amino-acyl tRNA molecules into the A site of the ribosome. This prevents incorporation of amino acid residues into elongating peptide chains. Tigecycline carries a glycylamido moiety attached to the 9-position of minocycline. The substitution pattern is not present in any naturally occurring or semisynthetic tetracydine and imparts certain microbiologic properties to Tigecycline. In general, Tigecycline is considered bacteriostatic; however, Tigecycline has demonstrated bactericidal activity against isolates of S. pneumoniae and L.pneumophila.
- Indications & Usage - Complicated skin and soft tissue infections, complicated intra-abdominal infections, community-Acquired Bacterial Pneumonia.
- Dosage & administration - The recommended dosage regimen for Tigecycline is an initial dose of 100 mg, followed by 50 mg every 12 hours. Intravenous infusions of Tigecycline should be administered over approximately 30 to 60 minutes every 12hours. The recommended duration of treatment with Tigecycline for complicated skin and skin structure infections or for complicated intra-abdominal infections is 5 to 14 days. The recommended duration of treatment with Tigecycline for community-acquired bacterial pneumonia is 7 to 14 days. The duration of therapy should be guided by the severity and site of the infection and the patient's clinical and bacteriological progress.
- Storage conditions - Store below 25°C. Protect from light moisture.